Odonate Therapeutics, Inc. (ODTC)
Odonate Therapeutics, Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $22005.00, up 29.44% on the session, giving a market capitalisation of $8.05B. On trailing twelve-month figures it carries a trailing P/E of 3227.62, a net margin of 0.0%. Its beta of 0.42 implies it has historically moved less than the broad market.
Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug. This agent is currently undergoing a Phase III clinical study for its application in patients suffering from metastatic breast cancer.
Odonate Therapeutics, Inc. is most often compared with the following Healthcare names: